On August 30th, Novartis’ Kymriah was approved by the U.S. Food & Drug Administration for treating a form of ALL (acute lymphoblastic leukemia) in individuals age 25 and younger. Kymriah, or tisagenlecleucel is a CAR-T (Chimeric Antigen Receptor T-Cell) therapy that, according to reports, is a one-time treatment. The treatment is customized to each patient, as his or her T-cells …
Trump Signs FDARA Into Law – Impact To Medical Products And Patients
On Friday August 18, President Trump signed FDARA (FDA Reauthorization Act 2017) into law. H.R. 2430 was passed by the House of Representatives on July 12, and the Senate passed the bill on August 3. This bipartisan legislation essentially reauthorizes the MDUFA (Medical Device User Fee Amendments), PDUFA (Prescription Drug User Fee Act), and other user fees that make it …
REA JET DOD 2.0 – Fastest Large Character Print Head On The Market!
When customers talk, we listen. REA JET is proud to announce we’ve taken steps to improve upon our legendary DOD (drop on demand) large character print head. Why improve on a component that’s already great? Customers desire faster production speeds, and a lower cost of ownership, with extended print head life. It’s that simple. Not only are our DOD 2.0 …
Pharma Marking – Treatment Of Ovarian Cancer Looks Promising
Recently it was announced that CA4P, an ovarian cancer treatment investigation drug of Mateon Therapeutics, was showing favorable results when combined with Roche’s Avastin, (bevacizumab) in a focus study assessing the effectiveness of the combination drugs along with chosen chemotherapy treatment in treating patients with prOC or platinum resistant ovarian cancer. According to reports, CA4P (combretastatin A-4 phosphate) targets the …
Pharma Coding – Bristol-Myers Squibb Acquires IFM Therapeutics
Recent news reports reveal that BMS and IFM Therapeutics have signed an agreement in which Bristol-Myers Squibb will acquire full rights to IFM’s NLRP3 and STING agonist programs in an effort to target innate immunity pathways that could potentially assist the body’s natural defenses in recognizing tumors and attacking them, expanding and complementing Bristol-Myers Squibb’s immuno-oncology portfolio. Reports claim BMS …